Abeona Therapeutics (ABEO) CFO sells shares to cover tax on awards

Rhea-AI Filing Summary

Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano sold 18,666 shares of common stock on January 22, 2026 at a weighted average price of $5.3309 per share. The filing explains that this sale was made to cover tax obligations tied to the vesting of restricted stock awards, meaning it was related to compensation rather than an open-market liquidation of a large personal position.

After this tax-related sale, Vazzano beneficially owned 568,560 shares of Abeona common stock directly. The reported price reflects multiple trades in a range from $5.33 to $5.38 per share, aggregated into a single weighted average figure in the filing.

Insider Trade Summary

Net Seller: 18,666 shares ($99,507)

Net Sell 1 txn

Insider Vazzano Joseph Walter

Role Chief Financial Officer

Sold 18,666 shs ($100K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,666	$5.3309	$100K

Holdings After Transaction: Common Stock — 568,560 shares (Direct)

Footnotes (1)

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazzano Joseph Walter

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S(1)		18,666	D	$5.3309(2)	568,560	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Joseph Vazzano	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ABEO’s CFO report on this Form 4?

Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano reported selling 18,666 shares of common stock on January 22, 2026.

At what price were the ABEO shares sold by the CFO?

The shares were sold at a weighted average price of $5.3309 per share, with individual trades executed in a price range from $5.33 to $5.38.

Why did the ABEO CFO sell 18,666 shares of stock?

The filing states that the sale was made to cover tax obligations associated with the vesting of restricted stock awards, indicating it was tied to equity compensation.

How many ABEO shares does the CFO own after this reported sale?

Following the transaction, Chief Financial Officer Joseph Walter Vazzano beneficially owned 568,560 shares of Abeona common stock, held directly.

Is the ABEO CFO’s ownership recorded as direct or indirect after the sale?

The Form 4 shows that the 568,560 shares are held directly by the CFO, with no indirect ownership nature indicated in the filing.

What does the weighted average sale price mean in this ABEO Form 4?

The filing notes that the $5.3309 figure is a weighted average price, as the 18,666 shares were sold in multiple transactions within the $5.33 to $5.38 range.